A regional court on Monday accepted an injunction request by Medytox against health authorities’ measures to revoke marketing licenses of Meditoxin and Coretox, allowing the South Korean botulinum toxin maker to continue selling those botox products until a full court trial comes to an end one or two years later.
Medytox had been at risk of losing two more of its product licenses after the Ministry of Food and Drug Safety announced product cancellation of 50, 100, 150 and 200 units of Meditoxin and Coretox in November upon finding the company had violated the law by trading the products overseas without its permission to leave the country. Those products were exported through a local wholesaler, but the ministry identified the ownership transfer to the wholesaler as domestic sale.
Medytox filed a lawsuit to nullify the administrative order along with a court stay. The Daejeon District Court warranted an injunction, challenging the ministry’s judgment against Medytox since its export transactions had been common in the industry.
Medytox said it will clarify its position on the ministry’s measures in the upcoming full court trial and focus on management normalization.
In June, the ministry canceled licenses of some Meditoxin products based on prosecutors’ investigations that the products were manufactured with unlicensed ingredients. But an appellate court accepted Medytox’s injunction request, which was appealed by the ministry to the Supreme Court, but the highest court ruled not to hear the appeal.
[ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved]